Sandeep Sehdev

Sandeep Sehdev

Université d'Ottawa - Ottawa / Canada
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4962845
University of Ottawa
person_outline Sandeep Sehdev's MOST POPULAR ARTICLES
1-) Patients\' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of …X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, ...Annals of oncology 25 (10), 1979-1987, 20142002014
2-) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2 …W Eiermann, T Pienkowski, J Crown, S Sadeghi, M Martin, A Chan, ...Journal of clinical oncology 29 (29), 3877-3884, 20111862011
3-) Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 … JR Mackey, T Pieńkowski, J Crown, S Sadeghi, M Martin, A Chan, ... Annals of Oncology 27 (6), 1041-1047, 2016 472016
4-) Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a …D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ...Annals of Oncology 32 (10), 1245-1255, 2021632021
5-) Challenges to implementation of an epidermal growth factor receptor testing strategy for non–small-cell lung cancer in a publicly funded health care systemPM Ellis, S Verma, S Sehdev, J Younus, NB LeighlJournal of Thoracic Oncology 8 (9), 1136-1141, 2013512013